Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for SBP and HRS Prophylaxis in Decompensated Cirrhosis
NCT05621005Phase 2Completed
- Start
- Mar 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS). Started Mar 2019; status: completed.
02
Drugs
rifaximin
03
Conditions
spontaneous bacterial peritonitis (SBP)hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on NCT05621005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621005.